---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042614"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:46:20.390991+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# CEO to present at ThinkEquity Conference; updates on Phase 2 glioblastoma trial and diagnostics

## Summary
- CEO Dr. Anatoly Dritschilo will present at ThinkEquity Conference on Oct 30, 2024 at 8:30am ET.
- Presentation covers Phase 2 trial of Ropidoxuridine for glioblastoma; no new data disclosed.
- Update on Shuttle Diagnostics subsidiary: predictive biomarkers for prostate cancer and PSMA ligand.
- Company posted updated investor presentation on its website; one-on-one meetings available.

## SEC filing metadata
- accession: 0001493152-24-042614
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224042614/0001493152-24-042614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224042614/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042614
- JSON: https://secwatch.observer/filing/0001493152-24-042614.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.